PACS developer Lockheed Martin Western Development Laboratories Medical Imaging Systems of Hoffman Estates, IL, has won two contracts worth nearly $10 million to install its Vantage PACS networks at two hospitals in Anchorage, AK.In the first
PACS developer Lockheed Martin Western Development Laboratories Medical Imaging Systems of Hoffman Estates, IL, has won two contracts worth nearly $10 million to install its Vantage PACS networks at two hospitals in Anchorage, AK.
In the first installation, Lockheed Martin won an $8.2 million bid to install a PACS network at Alaska Native Medical Center. The company will install 50 workstations to link different departments in the hospital, and the installation will include computed radiography, dry x-ray film printing, and teleradiology links.
At the other site, Lockheed Martin will install a PACS network worth $1.2 million at Elmendorf Air Force Base Hospital, where the radiology department plans to begin the transition to a filmless environment prior to moving into a new facility next year.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.